What will be Neuralink's next major technological update by end of 2025?
Increased electrode count • 25%
Extended battery life • 25%
New software features • 25%
Other major update • 25%
Neuralink press releases or major tech news outlets
Neuralink Implants Third Brain Device, Announces Updates and 2025 Plans at Las Vegas Event
Jan 11, 2025, 07:03 PM
Neuralink, the brain-computer interface company founded by Elon Musk, has successfully implanted its device in a third human patient. Musk announced during an event in Las Vegas, which was streamed on X, that all three implanted devices are functioning well. The company plans to conduct 20 to 30 more implants in 2025. The devices have been updated with additional electrodes and extended battery life. Neuralink is part of a growing field of startups developing brain implants aimed at treating conditions such as paralysis and ALS. The company is currently conducting two FDA-registered studies: the Prime Study, which allows paralyzed patients to control external devices like computers with their thoughts, and the Convoy Study, which explores controlling robotic arms. Neuralink's first patient, Noland Arbaugh, received the implant in 2024 and has used it to perform tasks such as navigating the internet and playing video games.
View original story
Other significant milestone • 25%
New treatment for epilepsy • 25%
Enhanced mobility for ALS patients • 25%
Improved communication for paralyzed patients • 25%
ALS treatment • 25%
Blindness treatment • 25%
Other breakthrough • 25%
Paralysis treatment • 25%
Enables multi-device control • 25%
Achieves full sensory feedback • 25%
Other • 25%
Significant AI integration • 25%
Case study on other neurological conditions • 25%
No high-profile case study • 25%
Case study on paralysis treatment • 25%
Case study on ALS treatment • 25%
Medical rehabilitation • 25%
Communication • 25%
Other • 25%
Gaming • 25%
Yes • 50%
No • 50%
Improvement in speech • 25%
Restoration of leg movement • 25%
Restoration of hand movement • 25%
Other • 25%
Yes • 50%
No • 50%
26 to 30 • 25%
More than 30 • 25%
Fewer than 20 • 25%
20 to 25 • 25%